Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL
The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Abstract
Hypoxia-inducible factor-1 (HIF-1) is a transcriptional complex that controls cellular and systemic homeostatic responses to oxygen availability. HIF-1 alpha is the oxygen-regulated subunit of HIF-1, an alpha beta heterodimeric complex. HIF-1 alpha is stable in hypoxia, but in the presence of oxygen it is targeted for proteasomal degradation by the ubiquitination complex pVHL, the protein of the von Hippel Lindau (VHL) tumour suppressor gene and a component of an E3 ubiquitin ligase complex. Capture of HIF-1 alpha by pVHL is regulated by hydroxylation of specific prolyl residues in two functionally independent regions of HIF-1 alpha. The crystal structure of a hydroxylated HIF-1 alpha peptide bound to VCB (pVHL, elongins C and B) and solution binding assays reveal a single, conserved hydroxyproline-binding pocket in pVHL. Optimized hydrogen bonding to the buried hydroxyprolyl group confers precise discrimination between hydroxylated and unmodified prolyl residues. This mechanism provides a new focus for development of therapeutic agents to modulate cellular responses to hypoxia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Under normoxia, PHDs hydroxylate conserved proline residues within HIF-α subunits, increasing their affinity for the von Hippel–Lindau (pVHL) E3 ubiquitin ligase complex, which promotes polyubiquitination and 26S proteasomal degradation”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [44]
In the citing paper
“The subsequent discovery of a peptide from hypoxia-inducible factor 1 subunit-α (HIF1α) that bound the E3 ligase von Hippel–Lindau tumour suppressor (VHL)18,19 led to the design of cell-penetrating PROTACs that degraded a range of POIs.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [18]
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination
Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., et al. (1998) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998003254 · Cited by 15,715
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648 · cited 1×
“Cycles of rebuilding and refinement were carried out using the programs”
MethodHershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
Self-citationAQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR
Laskowski, R., Rullmann, J. A., MacArthur, M., Kaptein, R., & Thornton, J. (1996) · Journal of Biomolecular NMR · doi:10.1007/bf00228148 · Cited by 5,502
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Self-citationHIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Research works printed but not linked: 1
- Hubbard, S. J. & Thornton, J. M. ‘NACCESS’, Computer Program Version 2.1.1 (Department of Biochemistry and Molecular Biology, Univ. Coll. London, London, 1996)
Cited by
Items 201–300 of 770
Optimal Translational Termination Requires C4 Lysyl Hydroxylation of eRF1
Feng, T., Yamamoto, A., Wilkins, S. E., Sokolova, E., Yates, L. A., Münzel, M., Singh, P., Hopkinson, R. J., Fischer, R., Cockman, M. E., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2013.12.028 · Cited by 108
Self-citationLi, L., Zhang, L., Zhang, X., Yan, Q., Minamishima, Y. A., Olumi, A. F., Mao, M., Bartz, S., & Kaelin, W. G. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00282-07 · Cited by 110
Yan, S., Yan, J., Liu, D., Li, X., Kang, Q., You, W., Zhang, J., Wang, L., Tian, Z., Lu, W., et al. (2021) · Theranostics · doi:10.7150/thno.59020 · Cited by 112
“Here we first of all designed a peptide-derived PROTAC that is capable of binding in crevices at the surfaces of MDMX and Von Hippel Lindau factor termed VHL (a component of the Cul2-Rbx1-EloB/C-VHL E3 ligase) (Figure 1) [21].”
VENGELLUR, A., WOODS, B. G., RYAN, H. E., JOHNSON, R. S., & LAPRES, J. J. (2003) · Gene Expression · doi:10.3727/000000003108749062 · Cited by 107
Huang, Y., Du, K.-M., Xue, Z.-H., Yan, H.-M., Li, D., Liu, W., Chen, Z., Zhao, Q., Tong, J.-H., Zhu, Y.-S., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403141 · Cited by 116
Determination and comparison of specific activity of the HIF‐prolyl hydroxylases
Tuckerman, J. R., Zhao, Y., Hewitson, K. S., Tian, Y.-M., Pugh, C. W., Ratcliffe, P. J., & Mole, D. R. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.09.005 · Cited by 105
Self-citationThe ubiquitin codes in cellular stress responses
Sheng, X., Xia, Z., Yang, H., & Hu, R. (2023) · Protein & Cell · doi:10.1093/procel/pwad045 · Cited by 130
“Once hydroxylated, HIF-α proteins have more than a 1,000-fold increase in binding affinity of the von-Hippel-Lindau protein (pVHL), which functions as the recognition component of a multi-sub-unit RING E3 ligase (VHL complex) containing Cullin-2, Elongin-1, Elongin-2, and Ring-Box 1 (RBX1) (Hon et al. 2002; Min et al.…”
BackgroundHIF and oxygen sensing; as important to life as the air we breathe?
Wiesener, M. S., & Maxwell, P. H. (2003) · Annals of Medicine · doi:10.1080/0785389031000458233 · Cited by 104
Self-citationBinding of Natively Unfolded HIF-1α ODD Domain to p53
Sánchez‐Puig, N., Veprintsev, D. B., & Fersht, A. R. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.11.019 · Cited by 116
Rechsteiner, M. P., von Teichman, A., Nowicka, A., Sulser, T., Schraml, P., & Moch, H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0757 · Cited by 103
Peptide blockade of HIFα degradation modulates cellular metabolism and angiogenesis
Willam, C., Masson, N., Tian, Y.-M., Mahmood, S. A., Wilson, M. I., Bicknell, R., Eckardt, K.-U., Maxwell, P. H., Ratcliffe, P. J., & Pugh, C. W. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162119399 · Cited by 103
Self-citationHIF-1α: a Valid Therapeutic Target for Tumor Therapy
Hong, S., Lee, H., & Kim, K. (2004) · Cancer Research and Treatment · doi:10.4143/crt.2004.36.6.343 · Cited by 125
Korbecki, J., Kojder, K., Barczak, K., Simińska, D., Gutowska, I., Chlubek, D., & Baranowska‐Bosiacka, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165647 · Cited by 106
“In chronic hypoxia the increase in HIF-α expression is dependent on the decrease in oxygen [86,92], whereas in cycling hypoxia it depends on Figure 3.”
BackgroundDixon, T., MacPherson, D., Mostofian, B., Dauzhenka, T., Lotz, S., McGee, D., Shechter, S., Shrestha, U. R., Wiewiora, R., McDargh, Z. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33575-4 · Cited by 99
HIF-1α Is Up-Regulated in Activated Mast Cells by a Process That Involves Calcineurin and NFAT
Walczak‐Drzewiecka, A., Ratajewski, M., Wagner, W., & Dastych, J. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.3.1665 · Cited by 113
“This results in HIF-1 accumulation and the formation of HIF-1 dimers (22).”
Backgroundp53 cannot be induced by hypoxia alone but responds to the hypoxic microenvironment
Pan, Y., Oprysko, P. R., Asham, A. M., Koch, C. J., & Simon, M. C. (2004) · Oncogene · doi:10.1038/sj.onc.1207657 · Cited by 110
“DFX and CoCl2 cause HIF stabilization via disruption of HIF prolyl hydroxylase iron binding; HIF prolyl hydroxylase function is required for rapid HIF-a protein degradation (Bruick and McKnight, 2001; Epstein et al., 2001; Jaakkola et al., 2001; Hon et al., 2002).”
BackgroundCurrent perspectives on antiangiogenesis strategies in the treatment of malignant gliomas
Jansen, M., Hamer, P. C. D. W., Witmer, A. N., Troost, D., & Noorden, C. J. F. V. (2004) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.03.001 · Cited by 107
Liu, J., & Nussinov, R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707401105 · Cited by 95
A survey of the year 2002 commercial optical biosensor literature
Rich, R. L., & Myszka, D. G. (2003) · Journal of Molecular Recognition · doi:10.1002/jmr.649 · Cited by 101
Lucas, X., & Ciulli, A. (2017) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.12.015 · Cited by 101
“VHL HIF-1α HIF-2α LxxLAHyp 1LM8 [41] 1LQB [42] VH298”
Hölscher, M., Silter, M., Krull, S., von Ahlen, M., Hesse, A., Schwartz, P., Wielockx, B., Breier, G., Katschinski, D. M., & Zieseniß, A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.186809 · Cited by 104
Posttranslationale Proteinmodifikation: die Chemie der Proteomdiversifizierung
Walsh, C. T., Garneau‐Tsodikova, S., & Gatto, G. J. J. (2005) · Angewandte Chemie · doi:10.1002/ange.200501023 · Cited by 94
Substrate-mediated Regulation of Cullin Neddylation
Chew, E.-H., & Hagen, T. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701153200 · Cited by 91
Sulfatase-Induced In Situ Formulation of Antineoplastic Supra-PROTACs
Chen, N., Zhang, Z., Liu, X., Wang, H., Guo, R.-C., Wang, H., Hu, B., Shi, Y., Zhang, P., Liu, Z., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c00826 · Cited by 93
Moon, Y., Cho, H., Kim, J., Song, S., Park, J. Y., Min, J. Y., Han, E. H., Kim, Y., Seong, J., Shim, M. K., et al. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202414146 · Cited by 111
Pheochromocytoma in Von Hippel-Lindau Disease
Hes, F. J., Höppener, J. W. M., & Lips, C. J. M. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021466 · Cited by 98
Hypoxia-dependent activation of HIF into a transcriptional regulator
Ruas, J. L., & Poellinger, L. (2005) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2005.04.001 · Cited by 102
Regulation of KLF4 Turnover Reveals an Unexpected Tissue-Specific Role of pVHL in Tumorigenesis
Gamper, A. M., Qiao, X., Kim, J., Zhang, L., DeSimone, M. C., Rathmell, W. K., & Wan, Y. (2012) · Molecular Cell · doi:10.1016/j.molcel.2011.11.031 · Cited by 90
Kontovinis, L., Papazisis, K. T., Touplikioti, P., Andreadis, C. B., Mouratidou, D., & Kortsaris, A. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-82 · Cited by 88
Hlatky, M. A., Quertermous, T., Boothroyd, D. B., Priest, J. R., Glassford, A. J., Myers, R., Fortmann, S. P., Iribarren, C., Tabor, H. K., Assimes, T. L., et al. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.07.042 · Cited by 91
Correlation between posttranslational modification and intrinsic disorder in protein.
Gao, J., & Xu, D. H. (2012) · PubMed · Cited by 88
Diabetic nephropathy: are there new and potentially promising therapies targeting oxygen biology?
Miyata, T., Suzuki, N., & de Strihou, C. V. Y. (2013) · Kidney International · doi:10.1038/ki.2013.74 · Cited by 88
Insights into Cullin-RING E3 Ubiquitin Ligase Recruitment: Structure of the VHL-EloBC-Cul2 Complex
Nguyen, H. C., Yang, H., Fribourgh, J. L., Wolfe, L. S., & Xiong, Y. (2015) · Structure · doi:10.1016/j.str.2014.12.014 · Cited by 96
“Apart from the ordering of this loop, the conformation of the VHL-EloBC subcomplex remains the same in the presence or absence of Cul2, with a Ca atom root-mean-square deviation (rmsd) of 0.8 Å (Figure 2C) (Hon et al., 2002; Min et al., 2002; Stebbins et al., 1999).”
InfluentialGeneration of a live attenuated influenza A vaccine by proteolysis targeting
Si, L., Shen, Q., Li, J., Chen, L., Shen, J., Xiao, X., Bai, H., Feng, T., Ye, A. Y., Li, L., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01381-4 · Cited by 94
Stimuli-activatable PROTACs for precise protein degradation and cancer therapy
Gao, J., Yang, L., Lei, S., Zhou, F., Nie, H., Peng, B., Xu, T., Chen, X., Yang, X., Sheng, C., et al. (2023) · Science Bulletin · doi:10.1016/j.scib.2023.04.028 · Cited by 87
A computational model of intracellular oxygen sensing by hypoxia-inducible factor HIF1α
Qutub, A. A., & Popel, A. S. (2006) · Journal of Cell Science · doi:10.1242/jcs.03087 · Cited by 87
The Hypoxia-Inducible Factor and Tumor Progression Along the Angiogenic Pathway
Brahimi-Horn, M. C., & Pouysségur, J. (2004) · International review of cytology · doi:10.1016/s0074-7696(04)42004-x · Cited by 100
Oxygen‐sensing mechanisms in cells
Wilson, J. W., Shakir, D., Batie, M., Frost, M., & Rocha, S. (2020) · The FEBS Journal · doi:10.1111/febs.15374 · Cited by 86
LANCASTER, D. E., McNEILL, L. A., McDONOUGH, M. A., APLIN, R. T., HEWITSON, K. S., PUGH, C. W., RATCLIFFE, P. J., & SCHOFIELD, C. J. (2004) · Biochemical Journal · doi:10.1042/bj20040735 · Cited by 86
Self-citationYan, L., Colandrea, V. J., & Hale, J. J. (2010) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2010.510836 · Cited by 86
Diabetic nephropathy: a disorder of oxygen metabolism?
Miyata, T., & de Strihou, C. V. Y. (2009) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.211 · Cited by 86
Hergovich, A., Lisztwan, J., Thoma, C. R., Wirbelauer, C., Barry, R. E., & Krek, W. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00232-06 · Cited by 84
“An analysis of the crystal structures of the VCB complex either unbound (38) or bound to a 20-amino-acid HIF1 peptide ( 15 , 32) fully supports our biochemical observation (see Fig. S3 in the supplemental material).”
ResultXu, Y., Zuo, Y., Zhang, H., Kang, X., Fei, Y., Yi, Z., Liu, M., Yeh, E. T. H., Chen, G., & Cheng, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.164236 · Cited by 86
Jiang, Y., Xue, Z.-H., Shen, W.-Z., Du, K.-M., Yan, H.-M., Yu, Y., Peng, Z.-G., Song, M.-G., Tong, J.-H., Chen, Z., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403734 · Cited by 87
Defective Tibetan PHD2 Binding to p23 Links High Altitude Adaption to Altered Oxygen Sensing
Song, D., Li, L.-S., Arsenault, P. R., Tan, Q., Bigham, A. W., Heaton-Johnson, K. J., Master, S. R., & Lee, F. S. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.541227 · Cited by 87
“We employed a VHL probe-based far Western analysis, because VHL binds with extremely high specificity to the prolyl hydroxylated form of HIF- (32, 33).”
MethodHaase, V. H. (2005) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2005.03.006 · Cited by 90
Targeting Protein–Protein Interactions in the HIF System
Wilkins, S. E., Abboud, M. I., Hancock, R. L., & Schofield, C. J. (2016) · ChemMedChem · doi:10.1002/cmdc.201600012 · Cited by 88
Self-citationThe structure and regulation of Cullin 2 based E3 ubiquitin ligases and their biological functions
Cai, W., & Yang, H. (2016) · Cell Division · doi:10.1186/s13008-016-0020-7 · Cited by 91
Russell, R. C., Sufan, R. I., Zhou, B. R., Heir, P., Bunda, S., Sybingco, S. S., Greer, S. N., Roche, O., Heathcote, S. A., Chow, V. W. K., et al. (2011) · Nature Medicine · doi:10.1038/nm.2370 · Cited by 83
“Discussion Mapping of VHL disease-associated mutations on the VHL–elongin B–elongin C (VBC) crystal structure engaged with HIF-1α peptide revealed two major VHL domains, α and β, that are required for elongin C and HIF-1α binding, respectivel”
BackgroundCorn, P. G., McDonald, E. R., Herman, J. G., & El‐Deiry, W. S. (2003) · Nature Genetics · doi:10.1038/ng1254 · Cited by 84
“Our analysis of pVHL mutants suggested that TBP-1 interacts with a region of the pVHL β domain (amino acids 136–154) that is distinct from the region that interacts with Hif1α (amino acids 67–117; ref”
BackgroundKoski, M. K., Hieta, R., Hirsilä, M., Rönkä, A. R., Myllyharju, J., & Wierenga, R. K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.014050 · Cited by 85
Mitochondrial complex III: An essential component of universal oxygen sensing machinery?
Chandel, N. S. (2010) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2010.08.004 · Cited by 95
The Role of Elongin BC-Containing Ubiquitin Ligases
Okumura, F., Matsuzaki, M., Nakatsukasa, K., & Kamura, T. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00010 · Cited by 91
Dao, J. H., Kurzeja, R. J. M., Morachis, J. M., Veith, H., Lewis, J. K., Yu, V. L., Tegley, C. M., & Tagari, P. C. (2008) · Analytical Biochemistry · doi:10.1016/j.ab.2008.09.052 · Cited by 81
“The pVHL–elongin B–elongin C heterotrimeric complex (VCB) was coexpressed in Escherichia coli and purified from the soluble fraction as described previously [16].”
MethodKnauth, K., Bex, C., Jemth, P., & Buchberger, A. (2005) · Oncogene · doi:10.1038/sj.onc.1209062 · Cited by 84
“The pVHL/ELC/ELB (VCB) subcomplex of CBCVHL can be recombinantly coexpressed in bacteria (Stebbins et al., 1999) and has been subject of crystallographic studies in the presence and absence of HIF-1a-derived substrate peptides (Stebbins et al., 1999; Hon et al., 2002; Min et al., 2002).”
BackgroundInfluentialBiochemical Diversity of 2-Oxoglutarate-Dependent Oxygenases
Hausinger, R. P. (2015) · 2-Oxoglutarate-Dependent Oxygenases · doi:10.1039/9781782621959-00001 · Cited by 72
Zhang, T., Xu, D., Liu, J., Wang, M., Duan, L., Liu, M., Meng, H., Zhuang, Y., Wang, H., Wang, Y., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-023-01170-4 · Cited by 74
Interaction of Hydroxylated Collagen IV with the von Hippel-Lindau Tumor Suppressor
Grosfeld, A., Stolze, I. P., Cockman, M. E., Pugh, C. W., Edelmann, M., Kessler, B., Bullock, A. N., Ratcliffe, P. J., & Masson, N. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611648200 · Cited by 71
Self-citationAscorbate Depletion: A Critical Step in Nickel Carcinogenesis?
Salnikow, K., & Kasprzak, K. S. (2005) · Environmental Health Perspectives · doi:10.1289/ehp.7605 · Cited by 80
Distinct aerobic and hypoxic mechanisms of HIF-α regulation by CSN5
Bemis, L., Chan, D. A., Finkielstein, C. V., Qi, L., Sutphin, P. D., Chen, X., Stenmark, K., Giaccia, A. J., & Zundel, W. (2004) · Genes & Development · doi:10.1101/gad.1180104 · Cited by 71
von Hippel–Lindau tumor suppressor: not only HIF's executioner
Czyzyk-Krzeska, M., & Meller, J. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.02.004 · Cited by 77
Puppala, D., Lee, H., Kim, K. B., & Swanson, H. I. (2008) · Molecular Pharmacology · doi:10.1124/mol.107.040840 · Cited by 70
“Apigenin-Protac[Ala] lacks the hydroxyproline moiety in the E3 ubiquitin recognition sequence, which is required for recruiting the specific ubiquitination machinery (Hon et al., 2002) and thereby serves as a negative control.”
BackgroundOpportunities and challenges of protein-based targeted protein degradation
Shen, F., & Dassama, L. M. K. (2023) · Chemical Science · doi:10.1039/d3sc02361c · Cited by 73
“22,23 Recently, more peptide-based PROTACs have been shown to successfully induce the degradation of proteins that include Akt, 24 Tau, 25 a -synuclein, 26 PI3K/ FRS2 a 27 and X-protein.”
The von Hippel-Lindau Tumor Suppressor Protein: Roles in Cancer and Oxygen Sensing
Kaelin, W. G. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.001 · Cited by 80
Evidence for a Stereoelectronic Effect in Human Oxygen Sensing
Loenarz, C., Mecinović, J., Chowdhury, R., McNeill, L. A., Flashman, E., & Schofield, C. J. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200805427 · Cited by 68
Self-citationRendon, B. E., Willer, S. S., Zundel, W., & Mitchell, R. A. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2009.01.001 · Cited by 70
Targeting the molecular basis for tumour hypoxia
Carroll, V. A., & Ashcroft, M. A. (2005) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399405009117 · Cited by 108
Kawabe, S., & Yokoyama, Y. (2011) · Marine Biotechnology · doi:10.1007/s10126-011-9394-3 · Cited by 77
“These two 4-hydroxyproline residues are recognized by an E3 ubiquitin ligase, von Hippel–Lindau tumorsuppressor protein (VHL); subsequently, ubiquitinated HIF-1α is degraded by the ubiquitin–proteasome system (Huang et al. 1998; Yu et al. 2001; Hon et al. 2002 ).”
BackgroundLeu‐574 of human HIF‐1α is a molecular determinant of prolyl hydroxylation
Kageyama, Y., Koshiji, M., To, K. K. W., Tian, Y., Ratcliffe, P. J., & Huang, L. E. (2004) · The FASEB Journal · doi:10.1096/fj.03-1233fje · Cited by 68
Self-citationBarbour, H., Nkwe, N. S., Estavoyer, B., Messmer, C., Gushul-Leclaire, M., Villot, R., Uriarte, M., Boulay, K., Hlayhel, S., Farhat, B., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106276 · Cited by 80
Cellular oxygen sensing in health and disease
Mole, D. R., & Ratcliffe, P. J. (2008) · Pediatric Nephrology · doi:10.1007/s00467-007-0632-x · Cited by 80
Self-citationSudhamsu, J., Lee, G. I., Klessig, D. F., & Crane, B. R. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804837200 · Cited by 74
Coleman, K. G., & Crews, C. M. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050430 · Cited by 66
“PROTAC-4 consists of a HIF-1α-based heptapeptide (pVHL7) that spans P564 and is known to bind to VHL (Hon et al. 2002); its targeting moiety is the artificial ligand AP21998 that selectively binds the F36V mutant of FKBP12 (Rollins et al.”
BackgroundEvaluation and Refinement of Sample Preparation Methods for Extracellular Matrix Proteome Coverage
McCabe, M. C., Schmitt, L. R., Hill, R. C., Dzieciątkowska, M., Maslanka, M. D., Daamen, W. F., Kuppevelt, T. H. V., Hof, D. J., & Hansen, K. C. (2021) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2021.100079 · Cited by 71
Chemical Inducers of Targeted Protein Degradation
Raina, K., & Crews, C. M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r109.078105 · Cited by 64
Degradation of target protein in living cells by small-molecule proteolysis inducer
Zhang, D., Baek, S.-H., Ho, A., & Kim, K. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.11.042 · Cited by 69
HIF targets in bone remodeling and metastatic disease
Johnson, R. W., Schipani, E., & Giaccia, A. J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.02.002 · Cited by 69
Structural basis of ubiquitylation
VanDemark, A. P., & Hill, C. P. (2002) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(02)00389-5 · Cited by 72
Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression
Chen, S., Li, X., Li, Y., Xing, Y., Geng, C., Gao, S., Li, J., Ma, B., Wang, Z., Lu, W., et al. (2022) · Theranostics · doi:10.7150/thno.75444 · Cited by 68
Huang, J., Yao, Z., Li, B., & Yuan, P. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.062 · Cited by 68
Li, Z., You, Q., & Zhang, X. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01596 · Cited by 65
Percy, M. J., Mooney, S. M., McMullin, M. F., Flores, A. G., Lappin, T. R. J., & Lee, F. S. (2003) · Molecular Cancer · doi:10.1186/1476-4598-2-31 · Cited by 70
“It may also be noted that this proline is conserved in all mammalian HIF-1α proteins for which sequence information is available, but is not present in either HIF-2α or HIF-3α, or in HIF-1α from Xenopus laevis [26].”
Hypoxia‐Inducible Factor Prolyl‐Hydroxylase: Purification and Assays of PHD2
Hewitson, K. S., Schofield, C. J., & Ratcliffe, P. J. (2007) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(07)35002-7 · Cited by 69
Self-citationErythrocytosis associated with a novel missense mutation in the BPGM gene
Petousi, N., Copley, R. R., Lappin, T. R. J., Haggan, S. E., Bento, C. M., Cario, H., Percy, M. J., The WGS Consortium, Ratcliffe, P. J., Robbins, P. A., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.109306 · Cited by 59
“corresponding residue in HIF-1! , Asp571, and PHD2 and VHL in the crystal structures of the respective complexes ( 21-23 ).”
BackgroundSelf-citationFurlow, P. W., Percy, M. J., Sutherland, S., Bierl, C., McMullin, M. F., Master, S. R., Lappin, T. R. J., & Lee, F. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808737200 · Cited by 58
Birle, D. C., & Hedley, D. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2722 · Cited by 58
Mutual regulation between SIAH2 and DYRK2 controls hypoxic and genotoxic signaling pathways
Pérez, M., García-Limones, C., Zapico, I., Marina, A., Schmitz, M. L., Muñóz, E., & Calzado, M. A. (2012) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjs047 · Cited by 59
“proteasome (Hon et al., 2002).”
Hypoxic regulation of the noncoding genome and NEAT1
Choudhry, H., & Mole, D. R. (2015) · Briefings in Functional Genomics · doi:10.1093/bfgp/elv050 · Cited by 62
Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design
Mi, D., Li, Y., Gu, H., Li, Y., & Chen, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115444 · Cited by 59
Forman, J., Worth, C. L., Bickerton, G. R., Eisen, T. G., & Blundell, T. L. (2009) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.22419 · Cited by 64
Hypoxia‐inducible factor signalling mechanisms in the central nervous system
Corcoran, A., & O'Connor, J. J. (2013) · Acta Physiologica · doi:10.1111/apha.12117 · Cited by 69
Balancing the Risks and Benefits of Oxygen Therapy in Critically Ill Adults
Budinger, G. R. S., & Mutlu, G. M. (2013) · CHEST Journal · doi:10.1378/chest.12-1215 · Cited by 67
Pereira, T., Zheng, X., Ruas, J. L., Tanimoto, K., & Poellinger, L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209297200 · Cited by 59
Iikuni, S., Ono, M., Watanabe, H., Shimizu, Y., Sano, K., & Saji, H. (2018) · Theranostics · doi:10.7150/thno.20982 · Cited by 56
“It is generally accepted that a deficit in the VHL gene contributes to HIF-1 stabilization, leading to a high level of CA-IX expression [1-5, 23].”
BackgroundInfluentialFandrey, J., Schödel, J., Eckardt, K., Katschinski, D. M., & Wenger, R. H. (2019) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-019-02334-8 · Cited by 60
Molecular diagnosis of tumor angiogenesis and anti-angiogenic cancer therapy
Sato, Y. (2003) · International Journal of Clinical Oncology · doi:10.1007/s10147-003-0342-8 · Cited by 61
“Tumor suppressor von Hippel Lindau (VHL) gene product (pVHL), which is found in a multiprotein complex with elongins B/C, forming an E3 ubiquitin ligase complex, regulates HIF-1α ubiquitination for degradation.(26,27) Thus, alteration of the VHL gene results in an increased amount of HIF-1α and HIF-1-mediated upregula…”
BackgroundDioxygenases as O2-dependent regulators of the hypoxic response pathway
Dann, C. E., & Bruick, R. K. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.08.140 · Cited by 62
Anderson, K. M., Nordquist, K. A., Gao, X., Hicks, K. C., Zhai, B., Gygi, S. P., & Patel, T. B. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.303222 · Cited by 62
Zheng, X., Yan, J., You, W., Li, F., Diao, J., He, W., & Yao, Y. (2021) · Small · doi:10.1002/smll.202100394 · Cited by 56
From Erythropoietin to Oxygen: Hypoxia-Inducible Factor Hydroxylases and the Hypoxia Signal Pathway
Ratcliffe, P. J. (2002) · Blood Purification · doi:10.1159/000065201 · Cited by 62
Self-citation
Metadata
- Authors
- Hon, W.-C., Wilson, M. I., Harlos, K., Claridge, T. D. W., Schofield, C. J., Pugh, C. W., Maxwell, P. H., Ratcliffe, P. J., Stuart, D. I., & Jones, E. Y.
- Affiliations
- University of Oxford (GB)
- Corresponding author
- Jones, E. Yvonne
- ORCID
- Venue
- Nature
- Published
- 2002-06
- Volume
- 417
- Issue
- 6892
- Pages
- 975-978
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2167786713
- Cited by
- 751
- References
- 31
- Citations by year
- 2026: 22 · 2025: 35 · 2024: 46 · 2023: 43 · 2022: 37 · 2021: 35 · 2020: 43 · 2019: 19 · 2018: 24 · 2017: 23 · 2016: 28 · 2015: 24 · 2014: 20 · 2013: 23 · 2012: 26
- FWCI
- 17.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Keywords
- HIF-1α, von Hippel-Lindau protein, E3 ubiquitin ligase, hypoxia, oxygen sensing, protein-protein binding, crystal structure, hydrogen bonding, ubiquitination, proteasomal degradation, transcriptional regulation
- MeSH terms
- Elongin, Amino Acid Sequence, Hypoxia, Binding Sites, Humans, Hydrogen Bonding, Hydroxylation, Hydroxyproline, Kinetics, Ligases, Models, Molecular, Molecular Sequence Data, Protein Binding, Protein Conformation, Structure-Activity Relationship, Substrate Specificity, Transcription Factors, Sequence Alignment, Crystallography, X-Ray, Surface Plasmon Resonance, Amino Acid Motifs, Tumor Suppressor Proteins, Ubiquitin-Protein Ligases, Von Hippel-Lindau Tumor Suppressor Protein, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.